247 related articles for article (PubMed ID: 14632747)
1. Comparative in vitro study of the immunomodulatory activity of humanized and chimeric anti-CD25 monoclonal antibodies.
Kircher B; Lätzer K; Gastl G; Nachbaur D
Clin Exp Immunol; 2003 Dec; 134(3):426-30. PubMed ID: 14632747
[TBL] [Abstract][Full Text] [Related]
2. Humanized anti-CD25 monoclonal antibody for prophylaxis of graft-vs-host disease (GVHD) in haploidentical bone marrow transplantation without ex vivo T-cell depletion.
Chen HR; Ji SQ; Wang HX; Yan HM; Zhu L; Liu J; Xue M; Xun CQ
Exp Hematol; 2003 Nov; 31(11):1019-25. PubMed ID: 14585364
[TBL] [Abstract][Full Text] [Related]
3. Prevention of acute allograft rejection in nonhuman primate lung transplant recipients: induction with chimeric anti-interleukin-2 receptor monoclonal antibody improves the tolerability and potentiates the immunosuppressive activity of a regimen using low doses of both microemulsion cyclosporine and 40-O-(2-hydroxyethyl)-rapamycin.
Hausen B; Gummert J; Berry GJ; Christians U; Serkova N; Ikonen T; Hook L; Legay F; Schuler W; Schreier MH; Morris RE
Transplantation; 2000 Feb; 69(4):488-96. PubMed ID: 10708100
[TBL] [Abstract][Full Text] [Related]
4. Monitoring of T-cell subsets in patients treated with anti-CD 25 antibody.
Praditpornsilpa K; Avihingsanon Y; Kupatawintu P; Songpanich S; Pisitkul T; Kansanabuch T; Eiam-Ong S; Chusil S; O-Charoen R; Tungsanga K
Transplant Proc; 2004 Mar; 36(2 Suppl):487S-491S. PubMed ID: 15041394
[TBL] [Abstract][Full Text] [Related]
5. Prophylactic effects of interleukin-2 receptor antagonists against graft-versus-host disease following unrelated donor peripheral blood stem cell transplantation.
Fang J; Hu C; Hong M; Wu Q; You Y; Zhong Z; Li W; Zou P; Hu Y; Xia L
Biol Blood Marrow Transplant; 2012 May; 18(5):754-62. PubMed ID: 21963619
[TBL] [Abstract][Full Text] [Related]
6. Anti-interleukin-2 receptor antibodies for the prevention of rejection in pediatric renal transplant patients: current status.
Swiatecka-Urban A
Paediatr Drugs; 2003; 5(10):699-716. PubMed ID: 14510627
[TBL] [Abstract][Full Text] [Related]
7. Anti-interleukin-2 receptor antibodies: basiliximab and daclizumab.
Pascual J; Marcén R; Ortuño J
Nephrol Dial Transplant; 2001 Sep; 16(9):1756-60. PubMed ID: 11522853
[No Abstract] [Full Text] [Related]
8. Identification of their epitope reveals the structural basis for the mechanism of action of the immunosuppressive antibodies basiliximab and daclizumab.
Binder M; Vögtle FN; Michelfelder S; Müller F; Illerhaus G; Sundararajan S; Mertelsmann R; Trepel M
Cancer Res; 2007 Apr; 67(8):3518-23. PubMed ID: 17440057
[TBL] [Abstract][Full Text] [Related]
9. Anti-interleukin-2 receptor antibodies in transplantation: what is the basis for choice?
Van Gelder T; Warlé M; Ter Meulen RG
Drugs; 2004; 64(16):1737-41. PubMed ID: 15301558
[TBL] [Abstract][Full Text] [Related]
10. IL-7 and IL-15 bypass the immunosuppressive action of anti-CD25 monoclonal antibodies.
Baan CC; Boelaars-van Haperen MJ; van Riemsdijk IC; van der Plas AJ; Weimar W
Transplant Proc; 2001 May; 33(3):2244-6. PubMed ID: 11377516
[No Abstract] [Full Text] [Related]
11. Immunosuppressive T-cell antibody induction for heart transplant recipients.
Penninga L; Møller CH; Gustafsson F; Gluud C; Steinbrüchel DA
Cochrane Database Syst Rev; 2013 Dec; (12):CD008842. PubMed ID: 24297433
[TBL] [Abstract][Full Text] [Related]
12. Basiliximab versus daclizumab combined with triple immunosuppression in deceased donor renal transplantation: a prospective, randomized study.
Kandus A; Arnol M; Omahen K; Oblak M; Vidan-Jeras B; Kmetec A; Bren AF
Transplantation; 2010 Apr; 89(8):1022-7. PubMed ID: 20075788
[TBL] [Abstract][Full Text] [Related]
13. [Monoclonal interleukin-2 receptor antibodies and their use in clinical kidney transplantation: basiliximab and daclizumab].
Madsen M; Svendsen UG
Ugeskr Laeger; 2000 Oct; 162(42):5648-52. PubMed ID: 11059309
[TBL] [Abstract][Full Text] [Related]
14. Short-term anti-CD25 monoclonal antibody administration down-regulated CD25 expression without eliminating the neogenetic functional regulatory T cells in kidney transplantation.
Wang Z; Shi BY; Qian YY; Cai M; Wang Q
Clin Exp Immunol; 2009 Mar; 155(3):496-503. PubMed ID: 19141125
[TBL] [Abstract][Full Text] [Related]
15. Daclizumab.
Mottershead M; Neuberger J
Expert Opin Biol Ther; 2007 Oct; 7(10):1583-96. PubMed ID: 17916050
[TBL] [Abstract][Full Text] [Related]
16. Anti-CD25 monoclonal antibody coverage allows for calcineurin inhibitor "holiday" in solid organ transplant patients with acute renal dysfunction.
Cantarovich M; Metrakos P; Giannetti N; Cecere R; Barkun J; Tchervenkov J
Transplantation; 2002 Apr; 73(7):1169-72. PubMed ID: 11965054
[TBL] [Abstract][Full Text] [Related]
17. Comparison of basiliximab and daclizumab with triple immunosuppression in renal transplantation.
Aktas S; Colak T; Baskin E; Sevmis S; Ozdemir H; Moray G; Karakayali H; Haberal M
Transplant Proc; 2011 Mar; 43(2):453-7. PubMed ID: 21440732
[TBL] [Abstract][Full Text] [Related]
18. Safe administration of a humanized murine antibody after anaphylaxis to a chimeric murine antibody.
Leonard PA; Woodside KJ; Gugliuzza KK; Sur S; Daller JA
Transplantation; 2002 Dec; 74(12):1697-700. PubMed ID: 12499883
[TBL] [Abstract][Full Text] [Related]
19. [Therapeutic strategy for acute rejection in organ transplantation--optimal use of monoclonal antibody].
Hanafusa T; Takahara S
Nihon Rinsho; 2002 Mar; 60(3):598-602. PubMed ID: 11904979
[TBL] [Abstract][Full Text] [Related]
20. The interleukin-2 inhibitors and their role in low-toxicity regimens.
Nashan B
Transplant Proc; 1999 Dec; 31(8A):23S-26S. PubMed ID: 10616557
[No Abstract] [Full Text] [Related]
[Next] [New Search]
